Rucaparib

Generic Name: rucaparib

Over-the-Counter (OTC)

Brand Names:

Rubraca

11 DESCRIPTION Rucaparib is an inhibitor of the mammalian polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme. The chemical name is 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic acid salt. The chemical formula of rucaparib camsylate is C 19 H 18 FN 3 O•C 10 H 16 O 4 S and the relative molecular mass is 555.67 Daltons.

Overview

Uses

1 INDICATIONS AND USAGE RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.

Dosage

2 DOSAGE AND ADMINISTRATION Recommended dose is 600 mg orally twice daily with or without food. ( 2.2 ) Continue treatment until disease progression or unacceptable toxicity. ( 2.2 ) For adverse reactions, consider interruption of treatment or dose reduction. ( 2.3 ) Patients receiving RUBRACA for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. ( 2.2 ) 2.1 Patient Selection Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer Select patients for the maintenance treatment of recurrent ovarian cancer with RUBRACA based on the presence of a deleterious BRCA mutation (germline and/or somatic) [see Clinical Studies ( 14.1 )].

Side Effects

6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling: Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions ( 5.1 )]. Most common adverse reactions (≥10%) among patients with ovarian cancer were nausea, fatigue (including asthenia), anemia, ALT/AST increased, vomiting, diarrhea, decreased appetite, thrombocytopenia, dysgeusia, neutropenia, blood creatinine increased, dyspnea, dizziness, dyspepsia, photosensitivity reaction, and leukopenia.

Interactions

7 DRUG INTERACTIONS 7.1 Effect of Rubraca on Other Drugs Certain CYP1A2, CYP3A, CYP2C9, or CYP2C19 Substrates Concomitant administration of Rubraca with CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates can increase the systemic exposure of these substrates [see Clinical Pharmacology ( 12.3 )] , which may increase the frequency or severity of adverse reactions of these substrates. If concomitant administration is unavoidable between Rubraca and substrates of these enzymes where minimal concentration changes may lead to serious adverse reactions, decrease the substrate dosage in accordance with the approved prescribing information.

Warnings

5 WARNINGS AND PRECAUTIONS Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): MDS/AML occurred in patients exposed to RUBRACA, and some cases were fatal. Monitor patients for hematological toxicity at baseline and monthly thereafter. Interrupt or reduce the dose based on severity of reaction. Discontinue if MDS/AML is confirmed. ( 2.3 , 5.1 ) Embryo-Fetal Toxicity: RUBRACA can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. ( 5.2 , 8.1 , 8.3 ) 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) occur in patients treated with RUBRACA, and are potentially fatal adverse reactions. 4 CONTRAINDICATIONS None. None. ( 4 )

Pregnancy

8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, Rubraca can cause fetal harm when administered to pregnant women. There are no available data in pregnant women to inform the drug-associated risk. In an animal reproduction study, administration of rucaparib to pregnant rats during organogenesis resulted in embryo-fetal death at maternal exposures that were 0.04 times the AUC 0-24h in patients receiving the recommended dose of 600 mg twice daily [see Data] . Apprise pregnant women of the potential risk to a fetus.

Storage

16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Rubraca is available as 200 mg, 250 mg, and 300 mg tablets. 200 mg Tablets: Blue, round, and debossed with “C2” on one side Supplied in bottles of 60 tablets (NDC:82154-0783-1) 250 mg Tablets: White, diamond, and debossed with “C25” on one side Supplied in bottles of 60 tablets (NDC:82154-0784-1) 300 mg Tablets: Yellow, oval, and debossed with “C3”...

Frequently Asked Questions

What is Rucaparib used for?▼

What are the side effects of Rucaparib?▼

Can I take Rucaparib during pregnancy?▼

What are the important warnings for Rucaparib?▼

Related Medications

Kreosotum 6c, Nitricum Acidum 6c, Thuja Occidentalis 6c, Pulsatilla Vulgaris 6c, Sepia Officinalis 6c

kreosotum 6c, nitricum acidum 6c, thuja occidentalis 6c, pulsatilla vulgaris 6c, sepia officinalis 6c

Kreosotum 6C HPUS* Nitricum Acidum 6C HPUS*................Vaginal Itching and Irritation Thuja Occidentalis 6C HPUS* Pulsatilla Pratensis 6C HPUS*................Vaginal Odor Sepia Officinalis 6C HPUS*................Vaginal Discharge *"HPUS" indicates the active ingredients are in the official Homeopathic Pharmacopeia of the United States.

Calcium Fluoride, Conium Maculatum Flowering Top, Lophophytum Leandrii, Hedera Helix Flowering Twig, Magnesium Carbonate, Cytisus Scoparius Flowering Top, Selenicereus Grandiflorus Whole, And Galium Aparine

calcium fluoride, conium maculatum flowering top, lophophytum leandrii, hedera helix flowering twig, magnesium carbonate, cytisus scoparius flowering top, selenicereus grandiflorus whole, and galium aparine

Non-Standardized Plant Allergenic Extract [EPC]

Regulative drops. Application of this homeopathic remedy for the designated usage is exclusively based on homeopathic experience. With severe forms of this disease, a clinically proven therapy is indicated.

Belladonna, Carduus Marianus, Chelidonium Majus, Chionanthus Virginica, Cinchona Officinalis, Colocynthis, Leptandra Virginica, Lycopodium Clavatum, Natrum Sulphuricum, Nux Vomica, Phosphorus, Ptelea Trifoliata, Pulsatilla (pratensis), Veratrum Album

belladonna, carduus marianus, chelidonium majus, chionanthus virginica, cinchona officinalis, colocynthis, leptandra virginica, lycopodium clavatum, natrum sulphuricum, nux vomica, phosphorus, ptelea trifoliata, pulsatilla (pratensis), veratrum album

Non-Standardized Plant Allergenic Extract [EPC]

PURPOSES: Belladonna – colic,** Carduus Marianus - headache,** Chelidonium Majus – right shoulder pain,** Chionanthus Virginica - constipation, Cinchona Officinalis - bloating,** Colocynthis - flatulence,** Leptandra Virginica - fever,** Lycopodium Clavatum – easy satiety, Natrum Sulphuricum – bitter taste,** Nux Vomica - nausea,** Phosphorus - fatigue,** Ptelea Trifoliata – abdominal discomfort,** Pulsatilla - indigestion,** Veratrum Album - diarrhea.** **Claims based on traditional homeopathic

Medical Disclaimer

This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.